Astra posts new late-stage trial win for COPD drug (AZN:NYSE)
Summary
AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a respiratory disease. Read more here...
Description
AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a respiratory disease. Read more here...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source